Syros Pharmaceuticals (SYRS)
(Real Time Quote from BATS)
$1.90 USD
-0.03 (-1.55%)
Updated Sep 25, 2024 11:00 AM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Price, Consensus and EPS Surprise
SYRS 1.90 -0.03(-1.55%)
Will SYRS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SYRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYRS
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
SYRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?
Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Other News for SYRS
Biotech Alert: Searches spiking for these stocks today
Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)
Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)
Syros Pharmaceuticals Reports SELECT-AML-1 Trial Outcomes
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences